BGB-53038 + tislelizumab

BGB-53038 + tislelizumab is a combination of a **pan-KRAS inhibitor** (BGB-53038) and an **anti-PD-1 monoclonal antibody** (tislelizumab, branded as Tevimbra). - **BGB-53038** acts by inhibiting multiple KRAS mutant and amplified forms present in solid tumors, disrupting downstream signaling pathways critical for tumor cell proliferation and survival. - **Tislelizumab** is a humanized IgG4 antibody selectively targeting PD-1 on T cells, preventing PD-1-mediated immunosuppression, and thereby enhancing anti-tumor immune response. The combination is under investigation in patients with nonsquamous non-small cell lung cancer (NSCLC) harboring KRAS mutations or amplifications. - This regimen is being evaluated in a first-in-human, multicenter, Phase 1a/1b trial to determine safety, tolerability, pharmacokinetics, and preliminary efficacy[1][3][4][7].

Other names

tislelizumab-jsgr